Tvardi Therapeutics (TVRD) Common Equity (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Common Equity of $14.5 million for Q1 2026, down 30.75% sequentially from $20.9 million in Q4 2025, and up 114.41% YoY from $6.8 million in Q1 2025.
Tvardi Therapeutics (TVRD) Common Equity (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Common Equity for 14 years, with the latest figure at $14.5 million in Q1 2026.
- Quarterly Common Equity rose 114.41% year-over-year to $14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.5 million (up 114.41% YoY) and the FY2025 annual result came in at $20.9 million, up 122.98% from the prior year.
- Common Equity fell to $14.5 million in Q1 2026 per TVRD's latest filing, from $20.9 million in the prior quarter.
- Over five years, Common Equity peaked at $204.4 million in Q2 2022 and troughed at -$100.6 million in Q1 2025.
- A 5-year average of $41.6 million and a median of $27.9 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2025: Common Equity plunged 191.66% in 2024, then surged 145.06% in 2025.
- Over 5 years, Common Equity stood at $158.8 million in 2022, then plunged by 139.08% to -$62.1 million in 2023, then plunged by 46.85% to -$91.1 million in 2024, then jumped by 122.98% to $20.9 million in 2025, then plunged by 30.75% to $14.5 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $14.5 million, $20.9 million, and $27.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.51 Mn |
| Dec 31, 2025 | 20.95 Mn |
| Sep 30, 2025 | 27.87 Mn |
| Jun 30, 2025 | 32.93 Mn |
| Mar 31, 2025 | -100.63 Mn |
| Dec 31, 2024 | -91.13 Mn |
| Sep 30, 2024 | -78.50 Mn |
| Jun 30, 2024 | -73.07 Mn |
| Mar 31, 2024 | -66.17 Mn |
| Dec 31, 2023 | -62.06 Mn |
| Sep 30, 2023 | 85.64 Mn |
| Jun 30, 2023 | 108.93 Mn |
| Mar 31, 2023 | 136.60 Mn |
| Dec 31, 2022 | 158.78 Mn |
| Sep 30, 2022 | 184.82 Mn |
| Jun 30, 2022 | 204.42 Mn |
| Mar 31, 2022 | 204.12 Mn |
| Dec 31, 2021 | 227.52 Mn |
| Sep 30, 2021 | 207.19 Mn |
| Jun 30, 2021 | 203.47 Mn |